newsfilter
← Latest News
Business Wire·

Cyclo Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Quarter marked by achievement of landmark milestone with completion of enrollment in pivotal Phase 3 study ("TransportNPC™") evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type